Athersys, Inc. (NASDAQ:ATHX) EVP John J. Harrington sold 15,000 shares of Athersys stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $2.17, for a total transaction of $32,550.00. Following the sale, the executive vice president now owns 679,416 shares in the company, valued at $1,474,332.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Athersys, Inc. (NASDAQ ATHX) traded up 7.14% on Tuesday, reaching $2.55. The company had a trading volume of 2,200,706 shares. Athersys, Inc. has a 12 month low of $1.02 and a 12 month high of $2.57. The company’s 50 day moving average price is $1.74 and its 200-day moving average price is $1.53. The company’s market capitalization is $290.47 million.

Athersys (NASDAQ:ATHX) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). Athersys had a negative return on equity of 121.47% and a negative net margin of 729.07%. The business had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.96 million. During the same quarter in the prior year, the firm posted ($0.08) earnings per share. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, equities analysts predict that Athersys, Inc. will post ($0.24) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/19/insider-selling-athersys-inc-athx-evp-sells-15000-shares-of-stock.html.

Several institutional investors and hedge funds have recently modified their holdings of ATHX. Vanguard Group Inc. lifted its stake in shares of Athersys by 19.5% during the first quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock valued at $6,668,000 after acquiring an additional 637,322 shares during the period. Royal Bank of Canada lifted its stake in shares of Athersys by 7,334.0% during the second quarter. Royal Bank of Canada now owns 380,846 shares of the biopharmaceutical company’s stock valued at $576,000 after acquiring an additional 375,723 shares during the period. State Street Corp lifted its stake in shares of Athersys by 27.2% during the second quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock valued at $2,161,000 after acquiring an additional 305,944 shares during the period. Northern Trust Corp lifted its stake in shares of Athersys by 30.8% during the second quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock valued at $1,697,000 after acquiring an additional 264,549 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Athersys by 35.2% during the first quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock valued at $1,292,000 after acquiring an additional 196,981 shares during the period. 19.08% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts recently weighed in on ATHX shares. Zacks Investment Research upgraded shares of Athersys from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Thursday, September 7th. Maxim Group set a $12.00 price objective on shares of Athersys and gave the company a “buy” rating in a research note on Monday, August 7th. Finally, ValuEngine raised Athersys from a “sell” rating to a “hold” rating in a report on Friday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Athersys has an average rating of “Buy” and a consensus target price of $7.17.

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.